AzurRx BioPharma (AZRX) Upsizes Previously Announced 5.5M Share Bought Deal offering to 9.1M Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
After-Hours Stock Movers 07/22: (SCKT) (SNAP) (TWTR) Higher; (SAM) (AZRK) Lower (more...)
July 22, 2021 5:51 PM EDTAfter-Hours Stock Movers
Socket Mobile (NASDAQ: SCKT) 88% HIGHER; reported Q2 EPS of $0.27, $0.24 better than the analyst estimate of $0.03. Revenue for the quarter came in at $6 million versus the consensus estimate of $4.07 million.
Boston Beer Co. (NYSE: SAM) 18.4% LOWER; reported Q2 EPS of $4.75, $2.10 worse than the analyst estimate of $6.85. Revenue for the quarter came in at $602.8 million versus the consensus estimate of $665.25 million.
AzurRx BioPharma (AZRX) Announces 5.5M Share Bought Deal Offering at $0.55/sh
July 22, 2021 4:52 PM EDTAzurRx BioPharma, Inc. (NASDAQ: AZRX) a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 5,454,546 shares of common stock of the Company, at a price to the public of $0.55 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 27, 2021, subject to satisfaction of customary closing... More
